JNJ vs MRK — Key Metrics
| Metric | JNJ (JOHNSON & JOHNSON) | MRK (MERCK & CO INC) |
|---|---|---|
| Price | 272.7 | 137.78 |
| Market Cap | 656.47 Billion | 339.66 Billion |
| P/E (TTM) | 40.82 | 137.78 |
| P/B (Quarterly) | 7.611 | 8.257 |
| P/S (TTM) | 6.61 | 5.04 |
| Net Profit Margin (TTM) | 16.2 | 3.6 |
| Gross Margin (TTM) | 67.6 | 71.8 |
| ROE (TTM) | 19.6 | 5.3 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Greatly Outperform
Recommendation Summary
Stock JNJ is projected to outperform the market, stock MRK is projected to greatly outperform the market. Upfront Recommendation: MRK.
Financial Metrics
| JNJ | Metrics | MRK |
|---|---|---|
| $272.70 | Price | $137.78 |
| — | Market Capitalization | — |
| 40.82 | Price to Earnings Ratio | 137.78 |
| 6.61 | Price to Sales | 5.04 |
| 31.88 | Price to FCF Ratio | 23.03 |
| 9.78 | Price to Gross Profit | 7.03 |
| 40.82 | Price to R&D | 11.04 |
| 11.65 | Price to Current Assets | 8.72 |
JNJ vs MRK at a glance
Johnson & Johnson (JNJ) and Merck & CO INC (MRK) are both Drug Manufacturers - General companies in the Healthcare sector. JNJ is the larger, at $656.5 billion in market value against $339.7 billion for MRK, about 1.9 times the size.
On trailing-twelve-month figures, JNJ trades at 40.8 times trailing earnings and MRK at 137.8; net profit margins are 16.2% and 3.6%.
The Upfront Investment model currently rates JNJ Outperform and MRK Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.